AI Assistant
Blog
Pricing
Log In
Sign Up
DOP051. Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
